Pride events face budget shortfalls as US corporations pull support ahead of summer festivities
Many U.S. corporations this year stopped supporting Pride events that celebrate LGBTQ+ culture and rights, causing hundreds of thousands of dollars in budget shortfalls ahead of the summer festivities and raising questions about corporate America's commitment to the cause.
The moves come as President Donald Trump has shown antipathy for trans protections and has attempted to roll back some LGBTQ+ friendly federal policies. Experts also note that a growing slice of the public has grown tired of companies taking a stance on social and political issues.
San Francisco Pride, the nonprofit that produces one of the country's largest and best-known LGBTQ+ celebrations, is facing a $200,000 budget gap after corporate donors dropped out. In Kansas City, Missouri, KC Pride lost about $200,000 — roughly half its annual budget.
Heritage of Pride, the umbrella organization behind NYC Pride and other LGBTQ+ events in New York City, is fundraising to narrow a $750,000 budget gap after companies withdrew.
Meanwhile, Budweiser brewer Anheuser-Busch ended its sponsorship of PrideFest in St. Louis, Missouri, its home base, after 30 years, leaving organizers with a $150,000 budget shortfall.
In response, many Pride organizations have canceled some dance parties, reduced the number of stages, hired less pricey headliners and no longer give volunteers free food or T-shirts.
But the core celebrations will go on. In San Francisco, this year's Pride theme is 'Queer Joy is Resistance.' In New York, it's 'Rise Up: Pride in Protest,' and, in Boston, it's 'Here to Stay!'
'If you come to Pride this year, that's a revolutionary act,' said Suzanne Ford, executive director of San Francisco Pride. 'You are sending a message to those in Washington that, here in San Francisco, we still have the same values that we've always had — you can love who you love here. We're not going to retreat from that.'
Following media coverage of their retreat, some companies changed course but asked that their names not be affiliated with the events, the event organizers said.
Corporations rethink Prid e sponsorships
San Francisco Pride earlier this year lost the support of five major corporate donors, including Comcast, Anheuser-Busch and Diageo, the beverage giant that makes Guinness beer and Smirnoff vodka.
'With everything we're facing from the Trump administration, to lose five of your partners within a couple of weeks, it felt like we were being abandoned,' Ford said.
After the withdrawals drew attention, some corporations said they would donate but only anonymously, Ford said, declining to identify those companies. As of this week, neither Comcast, Anheuser-Busch nor Diageo appeared on the organization's website as sponsors of the June 29 festivities. It was unclear if they donated.
Anheuser-Busch and Diageo didn't reply to emails from The Associated Press seeking comment. A spokesperson for Comcast also declined to comment but said some of its companies are sponsoring Silicon Valley Pride and Oakland Pride.
NYC Pride spokesperson Chris Piedmont said about 20% of its corporate sponsors either dropped their support or scaled back, including New York-based PepsiCo and Nissan.
Kyle Bazemore, Nissan North America's director of corporate communications, said the decision comes as the automaker reviews all of its marketing expenses to lower costs. PepsiCo did not return an email seeking comment.
Piedmont said NYC Pride has also received anonymous corporate funding and that he appreciates the unpublicized support.
'Writing a check to a nonprofit and supporting a nonprofit with no strings attached is stepping up to the plate,' Piedmont said.
Companies retreat from 'brand activism'
The shift reflects how corporations are adjusting to a changing cultural landscape that began during the pandemic and accelerated with Trump's second term, experts said.
'Companies are resourceful, they are clever at identifying trends and studying their environment and their customers' needs, but those needs change and corporations adjust,' said Amir Grinstein, a marketing professor at Northeastern University.
Corporations' presence in rainbow-filled Pride parades, concerts and dance parties became more ubiquitous after the landmark 2015 Supreme Court ruling that legalized same-sex marriage nationwide, as companies splashed their names on parade floats, rainbow flags and bright plastic bracelets.
So-called brand activism reached its peak between 2016 to 2022, a period of social upheaval around the pandemic, police brutality and transgender rights, Grinstein said.
But research has since found a growing number of American consumers don't want companies taking positions on such topics, said Barbara Kahn, a marketing professor at the University of Pennsylvania's Wharton School.
'There have always been people who said, 'I don't want my toothpaste to have an opinion, I just want to use my toothpaste,' but the tide has shifted, and research shows there are more people that feel that way now," Kahn said.
Pride organizers keep their distance from some corporations
Meanwhile, Republican-led states have been passing legislation to curtail diversity, equity and inclusion initiatives and LGBTQ+ rights, especially the ability of transgender young people to participate in sports or receive gender-affirming care.
Trump signed executive orders on his first day in office that rolled back protections for transgender people and terminated federal DEI programs.
Some companies followed suit by eliminating their DEI goals, prompting Pride organizations to sever ties.
San Francisco's organizers cut ties with Meta after the parent company of Facebook and Instagram terminated its DEI goals and content moderation policies.
Twin Cities Pride ended its relationship with Target over the Minneapolis-based retailer's curtailing of its DEI initiatives following a backlash from conservatives and the White House. The company's retreat from DEI policies led to a counter-boycott by civil rights advocates.
Target announced in May that sales fell more than expected in the first quarter due to customer boycotts, tariffs and other economic factors. The company now offers only some Pride products at a few stores and online.
Still, Rick Gomez, Target's chief commercial officer, told reporters in May that it's important to celebrate Heritage Months, which highlight different groups from Latinos to Asian Americans to the LGBTQ+ community.
"They drive sales growth for us,' he said.
Asking the community for financial support
First-time donations from individuals, foundations and local businesses have increased following corporate America's retreat.
In Minneapolis, a crowdfunding campaign by Twin Cities Pride to fill a $50,000 funding gap raised more than $89,000.
In San Francisco, two local foundations donated $55,000 combined.
'This isn't the first year that there's been an inflammatory climate around Pride,' said James Moran, a spokesperson for KC Pride, in Kansas City, Missouri. 'We know that our community is looking for spaces that are meant for us, where we can celebrate but also process what's going on and build our own support networks.'
___
Associated Press retail reporter Anne D'Innocenzio in New York City contributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
32 minutes ago
- Reuters
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
CHICAGO, June 1 (Reuters) - Treating breast cancer patients with AstraZeneca's (AZN.L), opens new tab experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' (NOVN.S), opens new tab Kisqali, Pfizer's (PFE.N), opens new tab Ibrance or Lilly's (LLY.N), opens new tab Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.
The Independent
33 minutes ago
- The Independent
Catholic students find refuge at Princeton University's worship space and cheer new pope
While other students might be in class or socializing at lunch, a group of young Catholics attends Mass every weekday at noon at the Princeton University Chapel. They sing Gregorian chants in Latin, pray and receive Communion at a side chapel — inside the huge, nondenominational Princeton Chapel — that young, devoted Catholics see as a sacred refuge in a mostly liberal and secular Ivy League environment. 'I feel that people's faith is so strong here,' student Logan Nelson said of the dedicated Catholic space where he attends daily Mass. 'It feels like a home — even more so than my own house.' A tight-knit Catholic campus ministry at a historic chapel The Gothic university chapel was built in 1928. At the time, Princeton says, its capacity to seat more than 2,000 people was second in size only to King's College Chapel at Cambridge University. Today, the chapel hosts interfaith services, concerts and weddings throughout the academic year and is known by the university as 'the bridge between town and gown.' On May 8, Catholic students were worshipping as usual at daily Mass in the side chapel when the service was interrupted by news alerts on their phones. In the Vatican, white smoke billowed from the Sistine Chapel, indicating that a new leader of their faith had been elected. The Rev. Zachary Swantek, Princeton's Catholic chaplain, told the group to gather at the Catholic Ministry office. Together, they watched on TV as the election of the first U.S.-born pope was announced. 'It was electric,' Nelson said, adding there was 'uproar' in the room when Chicago-born Cardinal Robert Prevost became the 267th pontiff. 'It was so cool to see an American pope.' Like other members of the Catholic ministry, he is hopeful that Pope Leo XIV will help bring a revival for Catholicism in America. 'I feel that there's a resurgence of Catholicism today,' said Nelson, who was religiously unaffiliated until last year when he converted to Catholicism. 'You see people who are passionate about their faith. There's a new wave coming, and we're going to have more converts like me, who are coming from the 'nones.'' Across much of the world, the number of people who are nonbelievers or unaffiliated with any organized religion has dramatically increased over the years. The people known as 'nones' — atheists, agnostics, or nothing in particular — comprise 30% or more of the adult population in the U.S., according to a survey by The Associated Press-NORC Center for Public Affairs Research. Princeton's Office of Religious Life says it supports members of the school community 'of any religious identity or of none.' Being a devoted Catholic on a mostly secular campus can be challenging; Swantek says he's never felt 'more needed as a priest.' He is proud of the tight-knit, welcoming Catholic community that he leads, and how they've helped recent converts come into the faith. A U.S.-born pope becomes a sign of hope for American Catholics News of the first U.S.-born pope was welcomed by Catholics across the ideological spectrum in Pope Leo XIV 's homeland. 'Something that did bring me a lot of hope is Pope Leo has a missionary background,' said Ace Acuna, a Princeton alumni. He recently attended a Mass at the chapel before beginning a nearly five-week Catholic pilgrimage from Indianapolis to Los Angeles. 'In a world where in some places it might look like faith is on the decline, a church that's willing to go out to the margins and evangelize and be on mission, that's going to be so important,' Acuna said. When he was an undergrad at Princeton, Acuna said the chapel became crucial to his college life. On his way to class every morning, he'd pass by the chapel for a silent prayer. He'd return for the noon Mass and again at the end of the day for one last prayer. 'Princeton is a very busy place and there's a lot of noise both externally but also internally because we're so busy and we're always worried about the next thing,' he said. 'Sometimes you just want silence, and you just want a place where you can lay down your burdens.' At the close of one recent Mass, David Kim and his girlfriend Savannah Nichols continued to pray near the altar, holding hands, kneeling or prostrating on the floor in a sign of reverence. Kim, a recent graduate of the Princeton Theological Seminary, converted to Catholicism last year and has been serving as an altar server at the Princeton University chapel. He called the chapel's side altar "an island of Christian life in an unbelieving world.' Princeton University has always had a vibrant religious community and a religiously diverse one, said Eric Gregory, a professor of religion there. 'In a way it's either so secular or even post-secular that it's not threatened by the Christian presence on campus,' he said. "Religious students in our campus are not cloistered from campus. They're also in sports teams, clubs and the newspaper. They're integrated.' Catholics students in Leo's home state cheer his election Catholics at the the University of Illinois at Urbana-Champaign were elated by his election — and reinvigorated in practicing their faith. 'Being able to live out my faith in this extremely secular campus is such a blessing to me,' said student Daniel Vanisko, a lifelong Catholic, later adding in an email that the pope's election 'really helps me to draw closer to my faith, seeing that someone that grew up in the same state as me, is the successor of Peter in the Church." Cavan Morber, a rising junior, said attending UIUC 'gives me chance to be challenged in my beliefs, think critically about what I believe, and share my faith with others.' Asked in an email exchange about the pope's election, Morber replied: 'What a time to be alive!' 'I am hopeful for how he will be able to unite the Church in a time of a lot of division among Catholics and everyone around the world,' Morber added. ___ Associated Press religion coverage receives support through the AP's collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content.
Reuters
37 minutes ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.
